AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 7262175
Drug: Both intravenous
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both intravenous and oral administration of prednisolone
Trial: 31365188
Drug: Individual ROS
RxNorm normalized name: RO-5045337
DrugBank: RO-5045337 (DB14793)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual ROS tablets
Trial: 26958466
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT) for chronic pain, 11-week duration
Trial: 22797843
Drug: Enhanced communication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced communication therapy specific to aphasia or dysarthria, offered by speech and language therapists for up to four months.
Trial: 22797843
Drug: Enhanced communication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced communication therapy
Trial: 21302487
Drug: Compound Danshen
RxNorm normalized name: DANSHEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compound Danshen Dripping Pill (CDDP) 10 pills, thrice daily for 18 months
Trial: 21302487
Drug: Compound Danshen
RxNorm normalized name: DANSHEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compound Danshen Dripping Pill (CDDP)
Trial: 21302487
Drug: Aspirin 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 0.1 g, once daily for 18 months
Trial: 21302487
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E 0.1 g, twice daily for 18 months
Trial: 12059064
Drug: Sedation with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sedation with 0.1 mg/kg of midazolam
Trial: 7605188
Drug: Polyethylene glycol
RxNorm normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyethylene glycol based bisacodyl suppositories (PGB)
Trial: 7605188
Drug: Hydrogenated vegetable
RxNorm normalized name: Hydrogenated Vegetable Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrogenated vegetable oil based bisacodyl suppositories (HVB)
Trial: 2371435
Drug: 200 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 micrograms inhaled salbutamol
Trial: 2371435
Drug: 12 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 micrograms inhaled formoterol
Trial: 2371435
Drug: 24 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24 micrograms inhaled formoterol
Trial: 349841
Drug: Subcutaneous injection
RxNorm normalized name: EPINEPHRINE 0.3 mg SUBCUTANEOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection of nitrous oxide in the lower extremities as part of conservative treatment.
Trial: 349841
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no nitrous oxide injection).
Trial: 31699572
Drug: Bihemispheric tDCS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bihemispheric tDCS combined with physical therapy (PT) and occupational therapy (OT)
Trial: 31699572
Drug: Sham bihemispheric
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham bihemispheric tDCS combined with physical therapy (PT) and occupational therapy (OT)
Trial: 29608733
Drug: Physical therapist-administered
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapist-administered physical activity intervention including a wearable activity tracking device, individualized step goals, and face-to-face feedback
Trial: 29608733
Drug: Standardized physical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized physical therapy alone after TKR
Trial: 24058189
Drug: Acetaminophen (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen (oral dose)
Trial: 23707270
Drug: Tanezumab (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tanezumab (5 or 10mg intravenous, up to 2 doses in 8-week intervals)
Trial: 23707270
Drug: Oxycodone (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone (10 to 40 mg every 12 hours)
Trial: 18657146
Drug: Combined oral
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined oral contraceptive (30 mug ethinyl estradiol and 150 mug levonorgestrel) administered daily for 21 days starting on the first day of the menstrual cycle.
Trial: 18657146
Drug: Combined oral
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined oral contraceptive (COC) in the first week of the cycle.
Trial: 3513357
Drug: Prostaglandin E1
RxNorm normalized name: Prostaglandin E1
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prostaglandin E1 (PGE1) at a dose of 30 ng/kg . min
Trial: 29287664
Drug: Acceptance and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acceptance and Commitment Therapy (ACT) in combination with Contingency Management (CM)
Trial: 29287664
Drug: ACT+CM in
RxNorm normalized name: ACT-101
DrugBank: ACT-101 (DB17000)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACT+CM in combination with modafinil
Trial: 22369682
Drug: High-dose proton
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose proton pump inhibitors (80 mg bolus, followed by pantoprazole 8 mg/h infusion, n = 100)
Trial: 22369682
Drug: Standard-dose proton
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose proton pump inhibitors (pantoprazole 40 mg bolus daily, n = 101)
Trial: 12576970
Drug: Mannitol administration
RxNorm normalized name: Mannitol
DrugBank: Mannitol (DB00742)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mannitol administration for >72 hrs (group 1)
Trial: 12576970
Drug: Mannitol administration
RxNorm normalized name: Mannitol
DrugBank: Mannitol (DB00742)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mannitol administration for 24 to 48 hrs (group 2)
Trial: 2002646
Drug: Cyclosporin A
RxNorm normalized name: Cyclosporin A
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporin A therapy (10 mg/kg/day)
Trial: 2002646
Drug: Blood transfusions
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood transfusions (3 to 5 third-party transfusions at two weekly intervals)
Trial: 30421537
Drug: Glecaprevir/Pibrentasvir (G/P)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glecaprevir/Pibrentasvir (G/P) 8-week treatment
Trial: 30421537
Drug: Glecaprevir/Pibrentasvir (G/P)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glecaprevir/Pibrentasvir (G/P) 12-week treatment
Trial: 30421537
Drug: Glecaprevir/Pibrentasvir (G/P)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glecaprevir/Pibrentasvir (G/P) 16-week treatment
Trial: 22669067
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy (CBT) including hypnosis; 6-session program
Trial: 22669067
Drug: Conservative standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative standard treatment for TMD
Trial: 15966131
Drug: Combination inhaled
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination inhaled corticosteroids and long acting beta agonists (ICS/LABA)
Trial: 10561258
Drug: Chemoradiation (epirubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemoradiation (epirubicin 60 mg/m(2)) followed by adjuvant chemotherapy (epirubicin 90 mg/m(2) at 4-week intervals for five cycles)
Trial: 8607100
Drug: Ethyl icosapentatenoate
RxNorm normalized name: Ethyl Acetate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethyl icosapentatenoate (EPA: 1800 mg/day) for 4 weeks
Trial: 1309115
Drug: hMG (FSH:LH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hMG (FSH:LH = 1:1) administered to 18 patients (group A)
Trial: 1309115
Drug: Highly purified
RxNorm normalized name: RAYON,PURIFIED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Highly purified hMG (FSH:LH = 19:1) administered to 19 patients (group B)
Trial: 3918356
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg sodium cromoglycate aerosol
Trial: 3918356
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg sodium cromoglycate aerosol
Trial: 3918356
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg sodium cromoglycate aerosol
Trial: 3918356
Drug: 12 mg
RxNorm normalized name: pectin 12 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 mg nebulised sodium cromoglycate
Trial: 30516064
Drug: 2016 American
RxNorm normalized name: American Ginseng
DrugBank: Panax quinquefolius whole (DB14296)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2016 American College of Sports Medicine guidelines (aerobic)
Trial: 30516064
Drug: 2016 American
RxNorm normalized name: American Ginseng
DrugBank: Panax quinquefolius whole (DB14296)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2016 American College of Sports Medicine guidelines (flexibility and resistance)
Trial: 26620682
Drug: Topical pharyngeal
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical pharyngeal anaesthesia
Trial: 22789440
Drug: Ceftriaxone (1g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone (1g intravenously in a single dose before surgery)
Trial: 22789440
Drug: Cefazolin (1g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefazolin (1g intravenously in a single dose before surgery)
Trial: 20508026
Drug: AS03(B) adjuvanted
RxNorm normalized name: hepatitis B surface antigen vaccine
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AS03(B) adjuvanted split virion vaccine
Trial: 20508026
Drug: Non-adjuvanted whole
RxNorm normalized name: HYACINTHOIDES NON-SCRIPTA WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-adjuvanted whole virion vaccine
Trial: 18593681
Drug: Insulin administered
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin administered via pen devices (n = 49)
Trial: 15973830
Drug: Ultrasonic periodontal
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ultrasonic periodontal treatment (Group 1)
Trial: 15973830
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (Group 3) - adults without PD, Community Periodontal Index of Treatment Needs = 0
Trial: 12048127
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid (FA) 5 mg/day
Trial: 12048127
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid (FA) 5 mg/day plus vitamin C 500 mg/day
Trial: 10453490
Drug: recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: recombinant human growth hormone (GH) 0.15 IU/(kg.day)
Trial: 10453490
Drug: recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: recombinant human growth hormone (GH)
Trial: 2455109
Drug: Nifedipine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (20 mg b.i.d. in a slow-release formulation)
Trial: 2455109
Drug: Nifedipine and
RxNorm normalized name: nifedipine and diuretics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine and Atenolol combination
Trial: 29476776
Drug: Propranolol (nonspecific
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (nonspecific β1‐, β2‐adrenergic receptor inverse agonist)
Trial: 27720505
Drug: S-AM/TEL 2.5/40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-AM/TEL 2.5/40 mg
Trial: 27720505
Drug: S-AM/TEL 5/40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-AM/TEL 5/40 mg
Trial: 27720505
Drug: TEL 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TEL 80 mg
Trial: 20820459
Drug: Zoom 2
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zoom 2 bleaching agent applied to labial surfaces
Trial: 20820459
Drug: No bleaching
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No bleaching treatment (Control)
Trial: 20820459
Drug: Polishing treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polishing treatment for both groups
Trial: 18005078
Drug: Supervised exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supervised exercise (twice weekly for 12 weeks)
Trial: 18005078
Drug: Control (normal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (normal treatment including encouragement to walk regularly)
Trial: 16633088
Drug: Indapamide (IND)
RxNorm normalized name: Indapamide
DrugBank: Indapamide (DB00808)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Indapamide (IND) 2.5 mg od
Trial: 16633088
Drug: Bendroflumethiazide (BDZ)
RxNorm normalized name: Bendroflumethiazide
DrugBank: Bendroflumethiazide (DB00436)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bendroflumethiazide (BDZ) 2.5 mg od
Trial: 14633756
Drug: Sufentanil TCI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil TCI (0.25 ng x ml(‐1) effect‐site concentration at extubation)
Trial: 14633756
Drug: Remifentanil TCI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil TCI with morphine bolus (0.15 mg x kg(‐1))
Trial: 8827850
Drug: 0.02 mg
RxNorm normalized name: escin 0.02 MG/MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.02 mg estradiol added to neuroleptic treatment for eight weeks
Trial: 8827850
Drug: Neuroleptic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neuroleptic treatment alone
Trial: 7967338
Drug: Aspirin, 320
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin, 320 mg/day
Trial: 30222637
Drug: Subcutaneous microneedle
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous microneedle RF treatment (67°C/4‐second duration)
Trial: 27977720
Drug: RBANS neurocognitive
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: RBANS neurocognitive test battery administered on admission and again at discharge (mean time 4.1 weeks, SD 1.86 weeks)
Trial: 25509967
Drug: Rajyoga meditation
RxNorm normalized name: benzalkonium chloride Topical Foam [Meditize]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rajyoga meditation in addition to routine medical treatment (analgesics and muscle relaxants)
Trial: 25509967
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (analgesics and muscle relaxants only)
Trial: 17706461
Drug: Multiplayer group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiplayer group (participated in a weekly IDSVG multiplayer class)
Trial: 10361649
Drug: Exercise training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise training plus relaxation therapy (relaxation group; n = 76)
Trial: 7741790
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg metoclopramide‐HCl (Cerucal)
Trial: 155507
Drug: Halcinonide-neomycin-amphotericin (HNA)
RxNorm normalized name: halcinonide / neomycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Halcinonide-neomycin-amphotericin (HNA) cream
Trial: 29136453
Drug: Locoregional interferon
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Locoregional interferon beta (3 million units once per day for 10 consecutive days every 8 weeks for a total of 3 courses, then 1-day injection every 4 weeks for 2.5 years)
Trial: 1511646
Drug: Loperamide (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loperamide (10 mg)
Trial: 1511646
Drug: Loperamide oxide
RxNorm normalized name: Loperamide oxide
DrugBank: Loperamide oxide (DB14661)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loperamide oxide (10 mg)
Trial: 23308361
Drug: Nutraceuticals containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutraceuticals containing soy isoflavones (60 mg) and berberine (500 mg)
Trial: 21127274
Drug: Aortic valve
RxNorm normalized name: VALVE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aortic valve replacement (AVR) with warfarin treatment
Trial: 19149269
Drug: Sodium ferulate
RxNorm normalized name: ferulate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium ferulate intravenous drip after 24 hours
Trial: 19149269
Drug: Basic treatment
RxNorm normalized name: Basic Fuchsin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basic treatment (dehydrating, cytidine diphosphocholine, controlling blood pressure, blood sugar and complicating diseases)
Trial: 12680747
Drug: Sertraline (adequate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline (adequate treatment)
Trial: 12680747
Drug: Placebo (adequate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (adequate treatment)
Trial: 10890988
Drug: Corticosteroids alone
RxNorm normalized name: abiraterone and corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroids alone (methylprednisolone or prednisolone at 1 mg/kg, increased by 50% every 5 to 10 days)
Trial: 10890988
Drug: Corticosteroids plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroids plus cyclosporine (5 mg/kg)
Trial: 8822971
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg SDZ‐WAG 994
Trial: 8822971
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg SDZ‐WAG 994
Trial: 8822971
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg SDZ‐WAG 994
Trial: 3913459
Drug: Oral acyclovir
RxNorm normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral acyclovir (200 mg 4 times daily) for up to 12 weeks
Trial: 3913459
Drug: Oral acyclovir
RxNorm normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral acyclovir and Placebo
Trial: 3913459
Drug: Placebo and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo and Oral acyclovir
Trial: 28549799
Drug: Pharmacist-led patient-centered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacist-led patient-centered pharmaceutical care (PC)
Trial: 23676632
Drug: Traditional Chinese
RxNorm normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional Chinese medicine (TCM) acupuncture (AP)
Trial: 23676632
Drug: Traditional Chinese
RxNorm normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional Chinese medicine (verum CHM)
Trial: 20152665
Drug: Rapid maxillary
RxNorm normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapid maxillary expansion (RME) during orthodontic treatment in group 1 (25 patients)
Trial: 18836152
Drug: Diagnosed diabetes
RxNorm normalized name: Diabetic Tussin EX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diagnosed diabetes (self-reported diabetes or diabetic medication use; n = 163)
Trial: 18836152
Drug: Undiagnosed diabetes
RxNorm normalized name: Diabetic Tussin EX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Undiagnosed diabetes (fasting blood glucose >or=7.0 mmol/L without diagnosed diabetes; n = 55)
Trial: 18836152
Drug: Impaired fasting
RxNorm normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Impaired fasting glucose (fasting blood glucose 5.6-6.9 mmol/L; n = 744)
Trial: 8632540
Drug: Preoperative M-VAC
RxNorm normalized name: M-2698
DrugBank: M-2698 (DB15431)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative M-VAC chemotherapy (2 courses before surgery and 3 courses after surgery)
Trial: 8632540
Drug: Postoperative M-VAC
RxNorm normalized name: M-2698
DrugBank: M-2698 (DB15431)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative M-VAC chemotherapy (5 adjuvant courses following cystectomy)
Trial: 8632540
Drug: Preoperative M-VAC
RxNorm normalized name: M-2698
DrugBank: M-2698 (DB15431)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative M-VAC chemotherapy
Trial: 8632540
Drug: Postoperative M-VAC
RxNorm normalized name: M-2698
DrugBank: M-2698 (DB15431)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative M-VAC chemotherapy
Trial: 26946729
Drug: menstrual cycle-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: menstrual cycle-based acupuncture therapy
Trial: 22293584
Drug: Statin +
RxNorm normalized name: Nystatin
DrugBank: Nystatin (DB00646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Statin + EPA (1,800 mg/day for 6 months)
Trial: 12401596
Drug: Caudal bupivacaine/neostigmine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caudal bupivacaine/neostigmine mixture (0.25% bupivacaine 1 mL/kg + neostigmine 2 micro g/kg)
Trial: 12401596
Drug: Caudal bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caudal bupivacaine (0.25% bupivacaine 1 mL/kg)